Protalix BioTherapeutics (PLX) Non-Current Assets (2010 - 2026)
Protalix BioTherapeutics' quarterly Non-Current Assets came in at $16.0 million in Q1 2026, up 19.45% year-on-year from $13.4 million in Q1 2025, and up 1.96% quarter-over-quarter from $15.7 million in Q4 2025.
Protalix BioTherapeutics has reported Non-Current Assets for 17 years, with the latest figure at $16.0 million in Q1 2026.
- For the quarter ending Q1 2026, Non-Current Assets rose 19.45% year-over-year to $16.0 million; the trailing twelve-month figure through Mar 2026 stood at $60.4 million (up 10.65% YoY), and the FY2025 full-year result was $15.7 million, up 17.5% from the prior year.
- Non-Current Assets for Q1 2026 stood at $16.0 million, up from $15.7 million in the prior quarter.
- The five-year high for Non-Current Assets was $16.0 million in Q1 2026, with the low at $10.9 million in Q4 2022.
- Average Non-Current Assets over 5 years is $13.5 million, with a median of $13.7 million recorded in 2024.
- Year-over-year, Non-Current Assets retreated 10.92% in 2022 and jumped 36.55% in 2023.
- Tracing PLX's Non-Current Assets over 5 years: stood at $10.9 million in 2022, then surged by 32.96% to $14.5 million in 2023, then fell by 8.02% to $13.3 million in 2024, then advanced by 17.5% to $15.7 million in 2025, then increased by 1.96% to $16.0 million in 2026.
- The last three Non-Current Assets figures came in at $16.0 million (Q1 2026), $15.7 million (Q4 2025), and $15.8 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | 4.56 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 62,953.78 |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 486.60 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | 5.83 Mn |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 30.30 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 14.75 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 22.66 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 910.24 Mn |
| 10 | Protalix BioTherapeutics | 164.49 Mn | 153.70 Mn | 29.62 Mn | 15.98 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 15.98 Mn |
| Dec 31, 2025 | 15.67 Mn |
| Sep 30, 2025 | 15.76 Mn |
| Jun 30, 2025 | 13.00 Mn |
| Mar 31, 2025 | 13.38 Mn |
| Dec 31, 2024 | 13.34 Mn |
| Sep 30, 2024 | 13.71 Mn |
| Jun 30, 2024 | 14.17 Mn |
| Mar 31, 2024 | 14.42 Mn |
| Dec 31, 2023 | 14.50 Mn |
| Sep 30, 2023 | 14.95 Mn |
| Jun 30, 2023 | 14.84 Mn |
| Mar 31, 2023 | 11.16 Mn |
| Dec 31, 2022 | 10.91 Mn |
| Sep 30, 2022 | 10.95 Mn |
| Jun 30, 2022 | 10.94 Mn |
| Mar 31, 2022 | 11.85 Mn |
| Dec 31, 2021 | 12.00 Mn |
| Sep 30, 2021 | 12.26 Mn |
| Jun 30, 2021 | 12.28 Mn |
| Mar 31, 2021 | 12.09 Mn |
| Dec 31, 2020 | 12.21 Mn |
| Sep 30, 2020 | 11.98 Mn |
| Jun 30, 2020 | 17.50 Mn |
| Mar 31, 2020 | 25.11 Mn |
| Dec 31, 2019 | 12.91 Mn |
| Sep 30, 2019 | 13.29 Mn |
| Jun 30, 2019 | 13.64 Mn |
| Mar 31, 2019 | 13.70 Mn |
| Dec 31, 2018 | 8.15 Mn |
| Sep 30, 2018 | 8.41 Mn |
| Jun 30, 2018 | 8.67 Mn |
| Mar 31, 2018 | 9.11 Mn |
| Dec 31, 2017 | 9.56 Mn |
| Sep 30, 2017 | 9.91 Mn |
| Jun 30, 2017 | 10.11 Mn |
| Mar 31, 2017 | 10.31 Mn |
| Dec 31, 2016 | 10.38 Mn |
| Sep 30, 2016 | 10.83 Mn |
| Jun 30, 2016 | 11.22 Mn |
| Mar 31, 2016 | 11.04 Mn |
| Dec 31, 2015 | 11.37 Mn |
| Dec 31, 2014 | 12.84 Mn |
| Mar 31, 2014 | 14.86 Mn |
| Dec 31, 2013 | 15.43 Mn |
| Sep 30, 2013 | 15.96 Mn |
| Jun 30, 2013 | 16.37 Mn |
| Mar 31, 2013 | 17.05 Mn |
| Dec 31, 2012 | 17.56 Mn |
| Sep 30, 2012 | 17.80 Mn |
| Jun 30, 2012 | 18.41 Mn |
| Mar 31, 2012 | 18.63 Mn |
| Dec 31, 2011 | 19.31 Mn |
| Sep 30, 2011 | 20.55 Mn |
| Jun 30, 2011 | 20.69 Mn |
| Dec 31, 2010 | 18.40 Mn |